【摘要】 目的 〖JP2〗探討血管內皮生長因子（VEGF）聯合血清腫瘤標志物對肺癌早期診斷意義。 方法 2008年1月-〖JP〗2009年8月收治的92例患者中肺癌患者64例，采集靜脈血清標本采用酶聯免疫法檢測其VEGF水平。 結果 64例肺癌與28例非肺癌患者VEGF表達水平分別為（255.72±566.00）、（299.46±795.8） pg/mL，兩者比較無統計學意義（Pgt;0.05）；43例中晚期肺癌VEGF值（125.07±68.2） pg/mL，表達顯著高于12例早期肺癌（196.00±260.60） pg/mL （Plt;0.05）；CEA與CYFRA21-1的表達對判斷26例發生胸膜轉移的肺癌有統計學意義（Plt;0.05）。 結論 結合血清VEGF水平和常規腫瘤標志物，可評估現狀及臨床分期，VEGF結合CEA與CYFRA21-1表達水平為預測肺癌患者早期發生胸膜轉移提供理論依據。【Abstract】 Objective To evaluate the effect of combined detection value of serum vascular endothelial growth factor (VEGF) and tumor markers on early diagnosis of lung cancer. Method Intravenous serum levels of VEGF and tumor markers were assayed by ELISA in 92 patients including 64 lung cancer from January 2008 to August 2009. Results The difference in serum levels of VEGF between the 64 patients with lung cancer [(255.72±566.0) pg/mL] and 28 health adult [(299.46±795.8) pg/mL] was not significant (Pgt;0.05). The level of VEGF in 43 patients with middle and late lung cancer [(125.07±68.2) pg/mL] was significantly higher than that in the 12 patients with early lung cancer [(196.00±260.60) pg/mL] (Plt;0.05). There were statistical significance in expression of serum CEA and CYFRA21-1 on diagnosis in 26 patients having lung cancer with early metastasis pleural fluid (Plt;0.05). Conclusion Combined diagnostic of serum VEGF and tumor markers can assess the state of an illness and clinical stage, and the serum levels of serum VEGF,CEA and CYFRA21-1 may be a good predictor for lung cancer with early metastasis pleural fluid.
